Wednesday, July 8, 2026

pharma · Critical Limb Ischemia (CLI) · Sarcoma · DSGN

Lxo Ireland Designated

Lxo Ireland Designated is a pharma organization headquartered in CARLSBAD, CA, IE. It trades on NYSE under ticker DSGN. Primary therapeutic focus areas include Critical Limb Ischemia (CLI), Sarcoma, Friedreich Ataxia, HP

CARLSBAD, CA, IE HQ
Public company Type
DSGN · NYSE Ticker
Company details
Clinical program

Cloxacilin

Phase 3 · small molecule · Staphylococcus

Cloxacilin for Staphylococcus is a Phase 3 program (small_molecule) at Lxo Ireland Designated Activity Company with 1 ClinicalTrials.gov record(s).

Internal code FPS-COL-2013-06

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Lxo Ireland Designated Activity Company
Phase
Phase 3
Modality
small_molecule
Indication
Staphylococcus
Status
terminated
Trials
1

Clinical trials